BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
1.465
+0.015 (1.03%)
At close: Mar 9, 2026, 4:00 PM EDT
1.480
+0.015 (1.02%)
After-hours: Mar 9, 2026, 4:00 PM EDT
BeyondSpring Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
60.24M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ImmuCell | 27.64M |
| TScan Therapeutics | 10.33M |
| NeurAxis | 3.36M |
| ImageneBio | 800.00K |
| Spruce Biosciences | 697.00K |
| Rallybio | 674.00K |
| Mereo BioPharma Group | 500.00K |
| Entera Bio | 124.00K |
BYSI News
- 4 weeks ago - BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference - GlobeNewsWire
- 3 months ago - BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewsWire
- 6 months ago - BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript) - Seeking Alpha
- 8 months ago - BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure - GlobeNewsWire
- 9 months ago - BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - GlobeNewsWire
- 10 months ago - BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewsWire
- 1 year ago - BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies - GlobeNewsWire